Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Irati Macaya(Foundation for Medical Research), Silvestre Vicent(Chartered Institute of Management Accountants)
Cited by 23
Related Papers
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
|Molecular Cancer|2018|306
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
|Nature Communications|2017|194
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
|Journal of Clinical Investigation|2019|50
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
|Molecular Cancer|2023|24
Anticancer Activity of RAS-GTP Inhibition in Cholangiocarcinoma
|Cancer Cell|2025|0